Tender Offer | ₹40.00 Crores | Listed at NSE, BSE | Fri, May 8, 2026 - Thu, May 14, 2026
Jagsonpal Pharmaceuticals Ltd. Buyback is a tender offer for the repurchase of up to 0.16 crore equity shares, representing 2.39% of the total paid-up equity share capital at a buyback price of ₹250 per share with a face value of ₹10 per share, aggregating to ₹40.00 crores.
The record date for determining eligible shareholders is May 4, 2026. Shareholders holding equity shares as on the record date are eligible to participate in the buyback.
The buyback opens on May 8, 2026 and closes on May 14, 2026, with the last date for receipt of tender forms being May 15, 2026.
The finalisation of buyback acceptance is expected on May 20, 2026, followed by settlement of bids on May 21, 2026.
Centrum Capital Ltd. is the Manager to the Buyback, MCS Share Transfer Agent Ltd. is the Registrar and Centrum Broking Ltd is the Registered Broker to the Buyback.
Investors are advised to refer to the Jagsonpal Pharmaceuticals Ltd. Letter of Offer for detailed information, including eligibility criteria, entitlement ratio, acceptance methodology, and tax implications.
Offer Opening Date
Fri, May 8, 2026
Offer Closing Date
Thu, May 14, 2026
Buyback Price
₹250 per share
Record Date
May 4, 2026
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 47 : 637 | 2,40,975 |
| General Category | 47 : 637 | 13,59,025 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
| Period Ended | 31 Mar 2025 | 31 Mar 2024 | 31 Mar 2023 |
|---|---|---|---|
| Assets | 278.26 | 217.08 | 194.95 |
| Total Income | 276.91 | 217.98 | 242.45 |
| Profit After Tax | 55.36 | 22.46 | 26.72 |
| Reserves and Surplus | 226.67 | 174.18 | 145.79 |
| Amount in ₹ Crore | |||
Founded in 1978, Jagsonpal Pharmaceuticals Ltd. is an Indian pharmaceutical company based in Gurgaon, specialising in manufacturing and marketing, with a dominant focus on gynaecology and orthopaedics. It operates as a top-tier player in women's health, offering formulations like tablets, injectables, and syrups, with a pan-India presence.
The company specialises in gynaecology (leader in progesterone) and orthopaedics, which constitute a significant portion of its business. They also have a presence in dermatology and pediatrics.
The company's production includes both in-house capabilities (Faridabad plant) and loan licensing, with a comprehensive quality management system that tests every batch.
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jan-2024 | 513.90 | 270.05 | 377.81 |
| Jan-2025 | 283.55 | 196.50 | 225.44 |
| Jan-2026 | 301.80 | 154.90 | 215.07 |
| Month | High Price | Low Price | Average Price |
|---|---|---|---|
| Jan-2024 | 514.85 | 273.60 | 377.59 |
| Jan-2025 | 284.36 | 196.35 | 225.37 |
| Jan-2026 | 301.65 | 155.00 | 214.95 |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
Jagsonpal Pharmaceuticals Ltd.
Plot No. 412-415,
Nimal Tower, 3rd Floor, Phase IV
Udyog Vihar Sector 18
Gurugram, Haryana, 122015
Lead Manager(s)
Registered Broker
The Jagsonpal Pharmaceuticals Buyback 2026 opens on May 8, 2026, and closes on May 14, 2026.
Last date to be eligible to participate in buyback is April 30, 2026.
The Jagsonpal Pharmaceuticals Buyback 2026 is a Tender Offer.
Jagsonpal Pharmaceuticals Buyback 2026 Schedule
| Buyback Opening Date | May 8, 2026 |
| Buyback Closing Date | May 14, 2026 |
| Last Date for receipt of Tender Forms | May 15, 2026 |
| Finalisation of Buyback Acceptance | May 20, 2026 |
| Last Date for settlment of bids | May 21, 2026 |
| Last Date for Extinguishment of Shares | June 2, 2026 |
The Jagsonpal Pharmaceuticals Buyback 2026 is being offered at Rs ₹250 per share.
| Category | Entitlement Ratio | Shares Offered |
|---|---|---|
| Small Shareholders | 47 : 637 | 2,40,975 |
| General Category | 47 : 637 | 13,59,025 |
Note:
Small Shareholders are retail shareholders under SEBI regulations.
General Category includes all other eligible shareholders.
Entitlement ratio is based on fully paid-up equity shares held on the record date.
The issue size of Jagsonpal Pharmaceuticals Buyback 2026 is 16,00,000 equity shares at ₹250 per share aggregating up to ₹40.00 Crores.
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
All the eligible Shareholders of the Company holding either Physical Shares or Demat Shares as on the Record Date can participate in the buyback offer through their Stock Broker.
The eligible shareholder holding the shares in Demat form needs to inform their broker the details of the Equity shares they wish to tender in the Buyback Offer. The shareholder needs to transfer the tendered shares to a Special account of the clearing corporation. The broker, in turn, would place an order on the stock exchange for the buyback.
The eligible shareholder holding the shares in physical form needs to approach their broker with original share certificates and supporting documents. Upon completion of document verification, the broker places an order on the stock exchange and submits the original share certificate and TRS to the registrar.
The tender form and TRS are optional in the case of Demat shares but mandatory in the case of physical shares.
The Jagsonpal Pharmaceuticals Buyback 2026 offers an opportunity for the shareholders to exit their positions at a premium price. In case you stay invested you would have an increased percentage of shareholding in the company and improved earnings per share. Thus, one should understand the company fundamentals along with one's need, goals, and risk appetite to decide if one wants to stay invested or participate in the buyback offer.
